Proceedings of the National Academy of SciencesGenetic & Genomic MedicinePeer-reviewed journal article
A proteomic signature of healthspan
Chia‐Ling KuoiD, Peiran Liu, Gabin DrouardiD, Eero VuoksimaaiD, Jaakko A. KaprioiD, Miina OllikaineniD, Zhiduo Chen, Luke C. PillingiD, Janice L. AtkinsiD, Richard H. FortinskyiD, George A. KucheliD, Breno Satler DiniziD
- Citations
- 23
- FWCI
- 7.28
- Field percentile
- top 2%
Abstract
The focus of aging research has shifted from increasing lifespan to enhancing healthspan to reduce the time spent living with disability. Despite significant efforts to develop biomarkers of aging, few studies have focused on biomarkers of healthspan. We developed a proteomics-based signature of healthspan (healthspan proteomic score (HPS)) using proteomic data from the Olink Explore 3072 assay in the UK Biobank Pharma Proteomics Project (53,018 individuals and 2920 proteins). A lower HPS was associated with higher mortality risk and several age-related conditions, such as COPD, diabetes, heart failure, cancer, myocardial infarction, dementia, and stroke. HPS showed superior predictive accuracy for these outcomes compared to other biological age measures. Proteins associated with HPS were enriched in hallmark pathways such as immune response, inflammation, cellular signaling, and metabolic regulation. The external validity was evaluated using the Essential Hypertension Epigenetics study with proteomic data also from the Olink Explore 3072 and complementary epigenetic data, making it a valuable tool for assessing healthspan and as a potential surrogate marker to complement existing proteomic and epigenetic biological age measures in geroscience-guided studies. SignificanceDespite substantial efforts to develop biomarkers of aging, few studies have focused on biomarkers of healthspan. The challenge lies in the need for long follow-up periods and large sample sizes of healthy individuals to observe aging outcomes. Therefore, developing surrogate biomarkers that can predict healthspan is crucial. We addressed this by developing a proteomics-based signature of healthspan, termed the Healthspan Proteomic Score (HPS), in a healthy cohort. We demonstrated its clinical, predictive, and biological validity in the UK Biobank and Essential Hypertension Epigenetics study, which represents a focused subset of the Finnish Twin Cohort. The HPS, serving as a surrogate marker of healthspan, is useful for gauging an individuals biological health and monitoring the impact of geroscience-guided interventions.
- organism: human
- assay: proteomics
- research focus: benchmarking
- research focus: variant effect prediction
- research focus: differential expression
- research focus: gene regulatory network inference
- approach: statistical model
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Plasma proteomics in the UK Biobank reveals youthful brains and immune systems promote healthspan and longevity
Hamilton Se‐Hwee Oh, Yann Le Guen, … Tony Wyss‐Coray·bioRxiv·Jun 7, 2024
- Proteomic aging clock (PAC) predicts age-related outcomes in middle-aged and older adults
Chia‐Ling Kuo, Zhiduo Chen, … Breno Satler Diniz·Aging CellPeer-reviewed·May 15, 2024
- A compact protein panel for organ-specific age and chronic disease prediction
Anastasiya Vladimirova, Ludger J.E. Goeminne, … Vadim N. Gladyshev·bioRxiv·Dec 9, 2024
- Intraindividual longitudinal changes of the proteome reveal dynamic markers of biological aging
Raphael Lermer, Xiaofeng Qian, … Matthias Heinig·bioRxiv·Oct 6, 2026
- Undulating changes in human plasma proteome across lifespan are linked to disease
Benoit Lehallier, David Gate, … Tony Wyss‐Coray·Nature MedicinePeer-reviewed·Dec 1, 2019
- Cellular Aging Signatures in the Plasma Proteome Record Human Health and Disease
Daisy Yi Ding, Veronica Augustina Bot, … Tony Wyss‐Coray·bioRxiv·Feb 12, 2026